Literature DB >> 12124798

Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3.

Angeliki Magklara1, Theodore J Brown, Eleftherios P Diamandis.   

Abstract

Accumulating evidence indicates that androgens and the androgen receptor modulate the development and progression of breast adenocarcinoma; however, the precise role and actions remain poorly defined. We examined previously the steroid hormone regulation of 2 known androgen-regulated kallikreins, KLK3 (encoding PSA) and KLK2 (encoding human kallikrein 2 or hK2) in BT-474, T-47D, ZR75-1, MCF-7, MFM-223 and BT-20 human breast cancer cells and found that they were differentially regulated, with the cells showing variable responses to androgen. To determine if this variable response was reflected by differences in androgen receptor, we characterized the expression of androgen receptor in these cells by Western blot analysis and saturation binding analysis. In addition, we sequenced androgen receptor cDNA from each of these cell lines to check whether any androgen receptor mutations were present. The expression of 11 nuclear receptor co-regulatory factors (SRC-1, AIB1, ARA24, ARA54, ARA55, ARA70, ARA160, FHL2, PDEF, NCoR1, SMRT) was compared in these cell lines by semi-quantitative RT-PCR to determine if the pattern of receptor co-activators or -repressors expressed in these cells might explain the differential regulation of KLK2 and KLK3. The levels of androgen receptor varied among the cell lines, but did not correlate with hK2 and PSA secretion determined previously. No mutations within the coding regions of the receptor were detected. With the exception of receptor expressed by MCF-7 cells, the polymorphic CAG repeat length was in the normal range. Every breast cancer cell line exhibited a distinct expression pattern of the nuclear receptor co-regulators examined raising the possibility that the relative levels of these co-activators/-repressors might differentially modulate androgen receptor transcriptional activity within the promoter/enhancer region of KLK2 and KLK3 of these cells. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12124798     DOI: 10.1002/ijc.10520

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

2.  Variable expression of nuclear receptor coactivator 4 (NcoA4) during mouse embryonic development.

Authors:  Alexandra Kollara; Theodore J Brown
Journal:  J Histochem Cytochem       Date:  2010-03-30       Impact factor: 2.479

3.  A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.

Authors:  Francois Lamoureux; Christian Thomas; Min-Jean Yin; Hidetoshi Kuruma; Ladan Fazli; Martin E Gleave; Amina Zoubeidi
Journal:  Clin Cancer Res       Date:  2011-02-24       Impact factor: 12.531

4.  Prolactin-induced protein is required for cell cycle progression in breast cancer.

Authors:  Ali Naderi; Marion Vanneste
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

5.  Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.

Authors:  Carolyn L Smith; Ilenia Migliaccio; Vaishali Chaubal; Meng-Fen Wu; Margaret C Pace; Ryan Hartmaier; Shiming Jiang; Dean P Edwards; M Carolina Gutiérrez; Susan G Hilsenbeck; Steffi Oesterreich
Journal:  Breast Cancer Res Treat       Date:  2012-09-27       Impact factor: 4.872

6.  Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Jessica Nearman; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors.

Authors:  Benford Mafuvadze; Yayun Liang; Cynthia Besch-Williford; Xu Zhang; Salman M Hyder
Journal:  Horm Cancer       Date:  2012-05-09       Impact factor: 3.869

8.  Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate.

Authors:  Georgia Papachristopoulou; Maroulio Talieri; Andreas Scorilas
Journal:  Tumour Biol       Date:  2012-10-20

9.  Contraceptive progestins with androgenic properties stimulate breast epithelial cell proliferation.

Authors:  Marie Shamseddin; Fabio De Martino; Céline Constantin; Valentina Scabia; Anne-Sophie Lancelot; Csaba Laszlo; Ayyakkannu Ayyannan; Laura Battista; Wassim Raffoul; Marie-Christine Gailloud-Matthieu; Philipp Bucher; Maryse Fiche; Giovanna Ambrosini; George Sflomos; Cathrin Brisken
Journal:  EMBO Mol Med       Date:  2021-05-27       Impact factor: 12.137

10.  Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.

Authors:  Mª Jesús Núñez-Iglesias; Silvia Novio; Carlota García; Mª Elena Pérez-Muñuzuri; María-Carmen Martínez; José-Luis Santiago; Susana Boso; Pilar Gago; Manuel Freire-Garabal
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.